Eisai And Biogen Announces Acceptance Of New Drug Submission (Nds) For Lecanemab

Eisai And Biogen Announced That Health Canada Has Accepted A New Drug Submission (Nds) For Lecanemab, An Investigational Anti-Amyloid Beta (A?) Protofibril* Antibody, For The Treatment Of Early Alzheimer